Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FQGY9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,332
Award facts
- Contract value 100% obligated
- $19,332.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19.3K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Trikafta 100-50-75 mg/150 mg tablets (84-count unit dosage). The delivery order, issued January 29, 2026, with an ultimate completion date of January 30, 2026, carries no set-aside designation, indicating the contractor competed on an unrestricted basis. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9B contract vehicle established November 13, 2025, through December 31, 2036.
The PPV-G GEN V represents DLA's broader $30.3B acquisition strategy to supply pharmaceutical products to Department of Defense military healthcare facilities worldwide. Trikafta is a branded cystic fibrosis treatment, consistent with DMS Pharmaceutical Group's extensive product portfolio spanning specialty pharmaceuticals, biologics, and routine medications. The contractor's demonstrated performance on numerous prior delivery orders and its established presence in the federal pharmaceutical supply chain since 2001 position it as a critical supplier within the DoD medical logistics network. No subcontractors are identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FQGY9?
SPE2DR26FQGY9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FQGY9 worth?
The government has obligated $19,332 on SPE2DR26FQGY9.
Is contract SPE2DR26FQGY9 an order under another contract?
Yes. SPE2DR26FQGY9 is a delivery order under SPE2DR25D9156, an indefinite delivery contract.
Was contract SPE2DR26FQGY9 competed?
The extent of competition for SPE2DR26FQGY9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award